A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories

NCT05514509 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

370

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: APRETUDE
DRUG: Cabotegravir tablet

Sponsor

ViiV Healthcare